1. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. (16th September 2022) Authors: Sborov, Douglas W.; Baljevic, Muhamed; Reeves, Brandi; Laubach, Jacob; Efebera, Yvonne A.; Rodriguez, Cesar; Costa, Luciano J.; Chari, Ajai; Silbermann, Rebecca; Holstein, Sarah A.; Anderson, Larry D.; Kaufman, Jonathan L.; Shah, Nina; Pei, Huiling; Patel, Sharmila; Cortoos, Annelore; Bartlett, J... Journal: British journal of haematology Issue: Volume 199:Number 3(2022) Page Start: 355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study. Issue 5 (18th February 2017) Authors: Taher, Ali T.; Origa, Raffaella; Perrotta, Silverio; Kourakli, Alexandra; Ruffo, Giovan Battista; Kattamis, Antonis; Goh, Ai‐Sim; Cortoos, Annelore; Huang, Vicky; Weill, Marine; Merino Herranz, Raquel; Porter, John B. Journal: American journal of hematology Issue: Volume 92:Issue 5(2017:May) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗